ShaileshSNandishMD
Cardiology • Springfield, ILAdult Congenital Heart Disease, Interventional Cardiology
Physician
Are you Dr. Nandish?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
619 E Mason St
Suite 4p57
Springfield, IL 62701Phone+1 217-788-0706Fax+1 217-525-2535
Summary
- Dr. Shailesh Nandish, MD is a cardiologist in Springfield, Illinois. He is currently licensed to practice medicine in Illinois, California, and Texas. He is affiliated with Enloe Medical Center.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Interventional Cardiology, 2010 - 2011- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Cardiovascular Disease, 2007 - 2010
Southern Illinois UniversityResidency, Internal Medicine, 1996 - 1999
Bangalore Medical CollegeClass of 1993
Certifications & Licensure
CA State Medical License 2019 - 2025
TX State Medical License 2007 - 2025
IL State Medical License 1996 - 2023
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 97 citationsWISP1, a Pro-mitogenic, Pro-survival Factor, Mediates Tumor Necrosis Factor-α (TNF-α)-stimulated Cardiac Fibroblast Proliferation but Inhibits TNF-α-induced Cardiomyoc...Kaliyamurthi Venkatachalam, Balachandar Venkatesan, Anthony J. Valente, Peter C. Melby, Sailesh Nandish
The Journal of Biological Chemistry. 2009-05-22 - 29 citationsVascular access complications: diagnosis and management.Raghu Kolluri, Brian C Fowler, Shailesh Nandish
Current Treatment Options in Cardiovascular Medicine. 2013-02-03 - 50 citationsCardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based TherapiesRobert J. Chilton, Jamison Wyatt, Shailesh Nandish, Rene A Oliveros, Michael Lujan
The American Journal of Medicine. 2011-01-01
Professional Memberships
- Member
